Clinical trials and recent progress in HIV vaccine development

Akmal Zubair,Bushra Bibi,Faiza Habib,Arooba Sujan,Muhammad Ali
DOI: https://doi.org/10.1007/s10142-024-01425-9
2024-08-31
Functional & Integrative Genomics
Abstract:The greatest obstacle for scientists is to develop an effective HIV vaccine. An effective vaccine represents the last hope for halting the unstoppable global spread of HIV and its catastrophic clinical consequences. Creating this vaccine has been challenging due to the virus's extensive genetic variability and the unique role of cytotoxic T lymphocytes (CTL) in containing it. Innovative methods to stimulate CTL have demonstrated significant therapeutic advantages in nonhuman primate model systems, unlike traditional vaccination techniques that are not expected to provide safe and efficient protection against HIV. Human clinical trials are currently evaluating these vaccination strategies, which involve plasmid DNA and live recombinant vectors. This review article covers the existing vaccines and ongoing trial vaccines. It also explores the different approaches used in developing HIV vaccines, including their molecular mechanisms, target site effectiveness, and potential side effects.
genetics & heredity
What problem does this paper attempt to address?